T cell-based immunotherapy (such as CAR therapies) is a promising approach for the treatment of several cancers. However, T cells currently employed for various T cell-based immunotherapies are usually senescent and terminally differentiated leading to poor proliferative and survival capacity, limiting their therapeutic effectiveness once transferred into a patient’s blood.
Researchers in the National Cancer Institute (NCI) Experimental Transplantation and Immunology Branch (ETIB) have epigenetically reprogrammed CD8+ T cell fate by overexpressing Phf19. The inventors found that overexpression of Phf19 in tumor-reactive CD8+ T cells limits T cell terminal differentiation and exhaustion. In addition, it was found that Phf19 overexpressing T cells exhibit enhanced proliferation and cytokine production, resulting in augmented anti-tumor activity in vivo. This technology is available for licensing and/or co-development.
- Treating cancer patients receiving T cell-based immunotherapy
- T cells overexpressing Phf19 can increase therapeutic effectiveness of adoptive immunotherapy because it improves T cell proliferation increasing the number of T cells that can be used for T cell-based immunotherapies
- T cells, overexpressing Phf19 used for immunotherapy in preclinical in vivo studies, are already known to induce a greater decrease in tumor size compared to mice treated with T cell-based immunotherapies using unmodified T cells
Yun Ji (NCI), Luca Gattinoni (NCI)
- U.S. Provisional: U.S. Provisional Patent Application Number 62/515,105 , Filed 05 Jun 2017